Arthrosi Therapeutics closed a $153 million Series E financing to fund completion of two Phase 3 trials for its gout candidate. The financing gives the San Diego biotech runway to deliver pivotal datasets expected in 2026 and positions the company to commercialize a potential next‑generation gout therapy. Investors cited the competitive landscape and the need for late‑stage capital to reach registrational readouts. The company emphasized the round will support dosing, enrollment and regulatory interactions for both trials. Market commentators note the raise arrives amid competition among San Diego biotechs aiming to capture the next gout treatment, and the money reduces execution risk ahead of the crucial Phase 3 data readouts.